

Please join us for an educational program

XOFLUZA: THE ONLY **SINGLE-DOSE** ORAL ANTIVIRAL FOR THE FLU

Tuesday, November 10, 2020
7:00 PM CST


PRESENTED BY
Cedric Spak, MD

RSVP AND PROGRAM DETAILS
EVENT CODE CM40074

AT

https://genentechrsvp.com?program_code=CM40074

<https://zoom.us/j/99656509037>



PROGRAM HIGHLIGHTS

-  **1 Recognize**
the substantial health burden associated with the flu
-  **2 Understand**
holistic flu management and the role of antiviral treatment
-  **3 Review**
the evidence for XOFLUZA across a broad patient spectrum
-  **4 Learn**
how you can counsel your flu patients on XOFLUZA

Indication

XOFLUZA™ is indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:

- otherwise healthy, or
- at high risk of developing influenza-related complications

Please see Important Safety Information on page 2.



Limitations of Use

Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.

CONTRAINDICATIONS

XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme.

IMPORTANT SAFETY INFORMATION

Hypersensitivity

Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in postmarketing experience with XOFLUZA. Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected. The use of XOFLUZA is contraindicated in patients with known hypersensitivity to XOFLUZA.

Bacterial Infections

There is no evidence of the efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

Drug Interactions

Co-administration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid co-administration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives or antacids, or oral supplements (eg, calcium, iron, magnesium, selenium, or zinc).

Concurrent Use with Live Attenuated Influenza Vaccine

The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and thereby decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.

Most Common Adverse Reactions

Adverse events (regardless of causality assessment) reported in at least 1% of adult and adolescent subjects (n=1,440) who received XOFLUZA at the recommended dose included diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%).

For additional important safety information, please see accompanying XOFLUZA full Prescribing Information.

You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting <http://www.fda.gov/medwatch> or calling 1-800-FDA-1088.

This event is sponsored by Genentech USA, Inc. No continuing education credits are offered with this program.

Minnesota, Vermont, and Federal Entities (e.g., the Department of Defense and the Department of Veterans Affairs) have restrictions on receiving in-kind benefits (e.g., meals, valet parking) at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict you from consuming any portion of the Genentech-sponsored meal at this program or from receiving any other in-kind benefit from Genentech (e.g., valet parking) in connection with the program.

When you RSVP please indicate whether you will accept or opt out of Genentech's in-kind benefits (e.g., meals, valet parking) at the program. If you choose to opt out you may either pay for the meal and parking on your own, or not consume anything at the program.

For all program attendees who receive Genentech's in-kind benefits at this program, Genentech will report the attendee's name and the value received as required by federal and state disclosure laws (for more information on the federal law please visit sunshine.gene.com).

The meal value reported may vary by event location and be up to \$150 per person (exceptions may apply).